Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
Conference Call and Webcast at 8:30AM Eastern Time
美国东部时间上午 8:30 的电话会议和网络直播
NEW YORK, May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Monday, May 13, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2024 financial results.
纽约，2024 年 5 月 2 日 /PRNewswire/ — Lucid 诊断公司 （纳斯达克股票代码：LUCD） （“Lucid” 或 “公司”）是一家处于商业阶段的癌症预防医学诊断公司，也是PAVMed Inc.（纳斯达克股票代码：PAVM，PAVMZ）的控股子公司，今天宣布，它将在美国东部时间2024年5月13日星期一上午8点30分举办业务最新情况电话会议和网络直播。在电话会议上，Lucid董事长兼首席执行官Lishan Aklog医学博士将提供最新业务情况，包括公司运营和持续增长战略概述。此外，Lucid的首席财务官丹尼斯·麦格拉思将讨论公司2024年第一季度的财务业绩。
The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.
该网络直播将在公司网站luciddx.com的投资者关系栏目播出。或者，要通过电话参加电话会议，美国的来电者应拨打1-800-836-8184，国际听众应拨打1-646-357-8785。所有听众都应向接线员提供电话会议名称 “Lucid Diagnostics 业务更新” 以供其加入。
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.
电话会议结束后，将在公司网站luciddx.com的投资者关系栏目上重播30天。
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool for at-risk patients to mitigate the risks of cancer and cancer deaths through early detection of esophageal precancer.
关于 Lucid 诊断
Lucid Diagnostics Inc. 是一家专注于癌症预防的商业阶段医疗诊断公司，也是PAVMed Inc.（纳斯达克股票代码：PAVM）的子公司。Lucid专注于数百万患有胃食管反流病（GERD）（也称为慢性胃灼热）的患者，他们有患食道癌前症和癌症的风险。Lucid 的 ESOGuard 食道DNA测试使用其ESOCheck食管细胞采集设备对在简短、无创的办公室程序中采集的样本进行，是第一种也是唯一一种市售诊断测试，能够作为高危患者的广泛筛查工具，通过早期发现食管癌前病来降低癌症和癌症死亡的风险。
For more information, please visit and for more information about its parent company PAVmed, please visit .
欲了解更多信息，请访问有关其母公司PavMed的更多信息，请访问。
SOURCE Lucid Diagnostics
来源 Lucid Diagno